| Drug            | Dosage  | Contraindications/warnings     | Selected references           |
|-----------------|---|--------------------------------|-------------------------------|
| vitamin D3      | 50,000 IU/die for 6 days (if not already taking as          | - severe chronic renal failure | Grant et al., 2020; Xu et al, |
|                 | prophylaxis) or 10,000 IU/day for 6 days (if already taking | - hypercalcemia                | 2020; Bae et al., 2020        |
|                 | as prophylaxis). Continue thereafter with 4,000 IU/day with |                                | https://c19vitamind.com/      |
|                 | a high-fat meal (i.e. at lunch). In children: 200 IU/Kg/day |                                |                               |
|                 | until a negative swab is obtained                           |                                |                               |
| vitamin C       | minimum 1 g/day, depending on formulation                   | - severe chronic renal failure | Bae et al., 2020; Holford et  |
|                 |   | - G6PD deficiency              | al., 2020; Colunga            |
|                 |   |                                | Biancatelli et al., 2020      |
|                 |   |                                | https://c19vitaminc.com/      |
| zinc picolinate | 30-50 mg/day  | - none                         | Wessels et al., 2020; Skalny  |
|                 |   |                                | et al., 2020                  |
|                 |   |                                | https://c19zinc.com/          |
| hesperidin      | 100 mg/day  | - none                         | Bellavite and Donzelli, 2020; |
|                 |   |                                | Adhikari et al., 2021         |
| quercetin       | up to 250 mg twice a day                                    | - none                         | Derosa et al., 2021; Colunga  |
|                 |   |                                | Biancatelli et al., 2020      |
|                 |   |                                | https://c19quercetin.com/     |
| lactoferrin     | up to 200 mg twice a day                                    | - none                         | Wang et al., 2020; Chang et   |
|                 |   |                                | al., 2020                     |
| bromhexine      | 8 mg three times a day.                                     | - none                         | Depfenhart et al., 2020       |

Supplementary Table 1. Vitamins and supplements recommended in COVID-19 phase 0 (asymptomatic with positive swab).

| Pelargonium sidoides  | 6 to 12 years of age: 13 mg 3 times a day for 7 days. Over | - haemorrhagic diathesis (for | Brendler et al., 2021        |
|-----------------------|--|-------------------------------|------------------------------|
|                       | 12 years of age: 20diatesi mg 3 times a day for 7 days     | example, treatment with       |                              |
|                       |  | anticoagulants)               |                              |
| fumigations           | 3 times a day  | - none                        |                              |
| hydroxytyrosol and α- | 2-3 oropharyngeal sprays 3-4 times a day                   | - none                        | Kiani et al., 2020; Carrouel |
| cyclodextrin          |  |                               | et al., 2021                 |
| vitamin A             | up to 30,000 IU/day  | - pregnancy                   | Trasino, 2020; Midha et al., |
|                       |  |                               | 2020                         |
| resveratrol           | up to 1,000 mg/day   |                               | Filardo et al., 2020         |

Important note: doctor will choose among the various options according to the profile and needs of individual patients. As a general recommendation,

vitamin D3, vitamin C and zinc picolinate should be always included in any plan, also in more advanced phases of COVID-19.

| Drug                  | Dosage  | Contraindications/warnings     | Selected references                    |
|-----------------------|---|--------------------------------|--|
| acetylsalicylic acid  | 100 mg/day until symptoms subside                   |                                | Bianconi et al., 2020; Cacciapuoti F,  |
|                       |   |                                | Cacciapuoti, 2021                      |
|                       |   |                                | https://c19aspirin.com/                |
| ivermectin            | 0.2 mg/kg up to 20 mg total dose. If insufficient   |                                | Kory et al., 2021; Marik and Kory,     |
|                       | clinical response, severe disease or obesity, daily |                                | 2021                                   |
|                       | dose can be increased up to 0.4-0.6 mg/kg           |                                | https://c19ivermectin.com/             |
| hydroxychloroquine    | 200 mg twice a day for 7 days                       | - arrhythmia                   | Nina and Dash, 2020; Sinha and         |
|                       |   | - retinopathy                  | Balayla, 2020; Million et al., 2021    |
|                       |   | - G6PD deficiency              | https://c19hcq.com/                    |
| azithromycin          | 500 mg/day for 3 days, stop for 2 days, then        | - long Q-T Syndrome            | Echeverría-Esnal et al., 2021; Million |
|                       | repeat  |                                | et al., 2021                           |
| doxycycline           | 100 mg twice a day for 7 days                       |                                | Yates et al., 2020                     |
| (as an alternative to |   |                                |  |
| azithromycin)         |   |                                |  |
| colchicine            | 0.5 mg twice a day for 14 days                      | - cardiac insufficiency        | Reyes et al., 2021                     |
|                       |   | - severe chronic renal failure | https://c19colchicine.com/             |

## Supplementary Table 2. Drugs recommended in COVID-19 phase 1 (symptomatic without signs of lung disease).

Important note: ivermectin, hydroxychloroquine and colchicine can be prescribed only with the patient's prior written informed consent, as required by Italian law (art. 3 paragraph 2 of the Law n. 94/98, published in the Official Gazette no. 86, 14 April 1998).

| Drug                              | Dosage                                 | Contraindications/warnings | Selected references               |
|-----------------------------------|--|----------------------------|-----------------------------------|
| amoxicillin/clavulanic acid       | 875 mg+125 mg 3 times a day for 8-10   |                            |                                   |
| (consider associating             | days                                   |                            |                                   |
| azithromycin in case of bacterial |  |                            |                                   |
| superinfection)                   |  |                            |                                   |
| enoxaparin                        | 4.000 IU/day for 10 days if <90 Kg bw  | - haemorrhagic diathesis   | Drago et al., 2020; Susen et al., |
|                                   | 6.000 IU/day for 10 days if >90 Kg bw  | - thrombocytopaenia        | 2020                              |
| levodropropizine                  | 60 mg as needed, up to 3 times a day   |                            |                                   |
| acetylcysteine                    | 600 mg up to 3 times a day for 7 days  |                            | Shi et al., 2020                  |
| montelukast                       | 10 mg 2 hours after dinner for 14 days |                            | Aigner et al., 2020               |

Supplementary Table 3. Drugs recommended in COVID-19 phase 2a (symptomatic with lung disease).

Important note: doctors may consider already in this phase glucocorticoids recommended in COVID-19 phase 2b.

| Therapy            | Dosage  | Contraindications/warnings              | Selected references    |
|--------------------|---|---|------------------------|
| oxygen therapy     | 1-6 L/min if SpO <sub>2</sub> <92% in ambient air (*) |   |                        |
| enoxaparin         | 100 IU/Kg/12 hours                                    |   | Drago et al., 2020;    |
|                    |   |   | Susen et al., 2020     |
| glucocorticoids    |   |   | Alexaki and Henneicke, |
|                    |   |   | 2021                   |
| dexamethasone      | 6 mg every morning or 3 mg twice a day                | - do not associate, use as alternatives |                        |
| betamethasone      | 8 mg every morning or 3 mg twice a day                | - use gastroprotection                  |                        |
| methylprednisolone | 32 mg every morning or 3 mg twice a day               | - carefully monitor for possible        |                        |
| prednisone         | 40 mg every morning or 3 mg twice a day               | and other common glucocorticoid-        |                        |
| deflazacort        | 30 mg twice a day                                     | associated adverse effects              |                        |
| antibiotics        | according to clinical judgement                       |   |                        |

Supplementary Table 4. Drugs recommended in COVID-19 phase 2b (symptomatic with lung disease and desaturation).

<u>Important note</u>: never use glucocorticoids at the beginning symptoms, wait until the end of the viremic phase. Treatment should be up to 6-7 days, thereafter taper off the drug. Prefer a single administration in the morning, consider two administrations in suffering patients. Deflazacort has a short half life and should be always given in two separate administrations.

(\*) hospitalization is mandatory whenever >6 L/min needed and/or SpO2 permanently < 92%.

## References

- Adhikari B, Marasini BP, Rayamajhee B, Bhattarai BR, Lamichhane G, Khadayat K, Adhikari A, Khanal S, Parajuli N. Potential roles of medicinal plants for the treatment of viral diseases focusing on COVID-19: A review. Phytother Res. 2021;35:1298-1312.
- Aigner L, Pietrantonio F, Bessa de Sousa DM, Michael J, Schuster D, Reitsamer HA, Zerbe H, Studnicka M. The Leukotriene Receptor Antagonist Montelukast as a Potential COVID-19 Therapeutic. Front Mol Biosci. 2020;7:610132.
- Alexaki VI, Henneicke H. The Role of Glucocorticoids in the Management of COVID-19. Horm Metab Res. 2021;53(1):9-15.
- Bae M, Kim H. Mini-Review on the Roles of Vitamin C, Vitamin D, and Selenium in the Immune System against COVID-19. Molecules. 2020;25(22):5346.
- Bellavite P, Donzelli A. Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits. Antioxidants (Basel). 2020;9(8):742.
- Bianconi V, Violi F, Fallarino F, Pignatelli P, Sahebkar A, Pirro M. Is Acetylsalicylic Acid a Safe and Potentially Useful Choice for Adult Patients with COVID-19? Drugs. 2020;80(14):1383-1396.
- Brendler T, Al-Harrasi A, Bauer R, Gafner S, Hardy ML, Heinrich M, Hosseinzadeh H, Izzo AA, Michaelis M, Nassiri-Asl M, Panossian A, Wasser SP, Williamson EM. Botanical drugs and supplements affecting the immune response in the time of COVID-19: Implications for research and clinical practice. Phytother Res. 2021;35(6):3013-3031.
- Cacciapuoti F, Cacciapuoti F. Could Low Doses Acetylsalicylic Acid Prevent Thrombotic Complications in COVID-19 Patients? Clin Appl Thromb Hemost. 2021;27:10760296211014592.
- Carrouel F, Gonçalves LS, Conte MP, Campus G, Fisher J, Fraticelli L, Gadea-Deschamps E, Ottolenghi L, Bourgeois D. Antiviral Activity of Reagents in Mouth Rinses against SARS-CoV-2. J Dent Res. 2021;100(2):124-132.

Chang R, Ng TB, Sun WZ. Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agents. 2020 Sep;56(3):106118.

- Colunga Biancatelli RML, Berrill M, Catravas JD, Marik PE. Quercetin and Vitamin C: An Experimental, Synergistic Therapy for the Prevention and Treatment of SARS-CoV-2 Related Disease (COVID-19). Front Immunol. 2020;11:1451.
- Depfenhart M, de Villiers D, Lemperle G, Meyer M, Di Somma S. Potential new treatment strategies for COVID-19: is there a role for bromhexine as add-on therapy? Intern Emerg Med. 2020;15(5):801-812.

Derosa G, Maffioli P, D'Angelo A, Di Pierro F. A role for quercetin in coronavirus disease 2019 (COVID-19). Phytother Res. 2021;35(3):1230-1236.

- Drago F, Gozzo L, Li L, Stella A, Cosmi B. Use of Enoxaparin to Counteract COVID-19 Infection and Reduce Thromboembolic Venous Complications: A Review of the Current Evidence. Front Pharmacol. 2020;11:579886.
- Echeverría-Esnal D, Martin-Ontiyuelo C, Navarrete-Rouco ME, De-Antonio Cuscó M, Ferrández O, Horcajada JP, Grau S. Azithromycin in the treatment of COVID-19: a review. Expert Rev Anti Infect Ther. 2021;19(2):147-163.
- Filardo S, Di Pietro M, Mastromarino P, Sessa R. Therapeutic potential of resveratrol against emerging respiratory viral infections. Pharmacol Ther. 2020;214:107613.
- Grant WB, Lahore H, McDonnell SL, Baggerly CA, French CB, Aliano JL, Bhattoa HP. Evidence that Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19 Infections and Deaths. Nutrients. 2020;12(4):988.
- Holford P, Carr AC, Jovic TH, Ali SR, Whitaker IS, Marik PE, Smith AD. Vitamin C-An Adjunctive Therapy for Respiratory Infection, Sepsis and COVID-19. Nutrients. 2020;12(12):3760.
- Kiani AK, Dhuli K, Anpilogov K, Bressan S, Dautaj A, Dundar M, Beccari T, Ergoren MC, Bertelli M. Natural compounds as inhibitors of SARS-CoV-2 endocytosis: A promising approach against COVID-19. Acta Biomed. 2020;91(13-S):e2020008.
- Kory P, Meduri GU, Varon J, Iglesias J, Marik PE. Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the Prophylaxis and Treatment of COVID-19. Am J Ther. 2021;28(3):e299-e318.
- Marik PE, Kory P. Ivermectin, A Reanalysis of the Data. Am J Ther. 2021;28(5):e579-e580.
- Midha IK, Kumar N, Kumar A, Madan T. Mega doses of retinol: A possible immunomodulation in Covid-19 illness in resource-limited settings. Rev Med Virol. 2020:e2204.
- Million M, Roussel Y, Gautret P, Raoult D. Effect of hydroxychloroquine and azithromycin on SARS-CoV-2 clearance in COVID-19 patients, a metaanalysis. Int J Antimicrob Agents. 2021;57(1):106240.
- Nina PB, Dash AP. Hydroxychloroquine as prophylaxis or treatment for COVID-19: What does the evidence say? Indian J Public Health. 2020;64(Supplement):S125-S127.

- Reyes AZ, Hu KA, Teperman J, Wampler Muskardin TL, Tardif JC, Shah B, Pillinger MH. Anti-inflammatory therapy for COVID-19 infection: the case for colchicine. Ann Rheum Dis. 2021;80(5):550-557.
- Shi Z, Puyo CA. Ther Clin Risk Manag. N-Acetylcysteine to Combat COVID-19: An Evidence Review. 2020;16:1047-1055.
- Sinha N, Balayla G. Hydroxychloroquine and COVID-19. Postgrad Med J. 2020;96(1139):550-555.
- Skalny AV, Rink L, Ajsuvakova OP, Aschner M, Gritsenko VA, Alekseenko SI, Svistunov AA, Petrakis D, Spandidos DA, Aaseth J, Tsatsakis A, Tinkov AA. Zinc and respiratory tract infections: Perspectives for COVID-19 (Review). Int J Mol Med. 2020;46(1):17-26.
- Susen S, Tacquard CA, Godon A, Mansour A, Garrigue D, Nguyen P, Godier A, Testa S, Levy JH, Albaladejo P, Gruel Y; GIHP and GFHT. Prevention of thrombotic risk in hospitalized patients with COVID-19 and hemostasis monitoring. Crit Care. 2020;24(1):364.
- Trasino SE. A role for retinoids in the treatment of COVID-19? Clin Exp Pharmacol Physiol. 2020;47(10):1765-1767.
- Wang Y, Wang P, Wang H, Luo Y, Wan L, Jiang M, Chu Y. Lactoferrin for the treatment of COVID-19 (Review). Exp Ther Med. 2020;20(6):272.
- Wessels I, Rolles B, Rink L. The Potential Impact of Zinc Supplementation on COVID-19 Pathogenesis. Front Immunol. 2020;11:1712.
- Xu Y, Baylink DJ, Chen CS, Reeves ME, Xiao J, Lacy C, Lau E, Cao H. The importance of vitamin d metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19. J Transl Med. 2020;18(1):322.
- Yates PA, Newman SA, Oshry LJ, Glassman RH, Leone AM, Reichel E. Doxycycline treatment of high-risk COVID-19-positive patients with comorbid pulmonary disease. Ther Adv Respir Dis. 2020;14:1753466620951053.